The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

Autor: Stewart Coats, Andrew J., Srinivasan, Venkatesan, Surendran, Jayaraman, Chiramana, Haritha, Vangipuram, Shankar R. K. G., Bhatt, Nirajkumar N., Jain, Minish, Shah, Sandip, Ali, Irfhan A. B. H., Fuang, Ho G., Hassan, Mohammed Z. M., Beadle, John, Tilson, Julia, Kirwan, Bridget-Anne, Anker, Stefan D.
Zdroj: Journal of Cachexia, Sarcopenia & Muscle; Dec2011, Vol. 2 Issue 4, p201-207, 7p
Databáze: Complementary Index
Externí odkaz: